Adenocarcinoma, Follicular: all 49 studies
Page 1 of 1. Open to participants first (7), then studies with results posted, then the rest; newest registration first within each.
- Bethesda Classification and Risk Stratification in Differentiated Thyroid CarcinomaNot yet recruitingNCT07858097
- Health and Wellness Coaching to Improve Adherence to Healthy Habits and Treatment Plans in Papillary and Follicular Thyroid Cancer SurvivorsRecruitingNCT07545837Not applicable
- Personalized Cancer Support (Thrive Track) to Manage the Emotional Needs of Young Adults With Thyroid, Melanoma and Testicular Cancer, PerCS-YA TrialNot yet recruitingNCT07529080Not applicable
- XL092 for the Treatment of Locally Advanced or Metastatic Radioiodine Refractory Differentiated Thyroid CancerRecruitingNCT06959641Phase 2
- Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E MutationRecruitingNCT06440850Phase 2
- Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TCRecruitingNCT05668962Phase 2
- Studies on Tumors of the ThyroidRecruitingNCT00001160
- Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid CancerActive, not recruitingNCT03914300Phase 2Results posted
- Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY TrialTerminatedNCT03753919Phase 2Results posted
- A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted TherapyActive, not recruitingNCT03690388Phase 3Results posted
- Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid CancerTerminatedNCT03630120Phase 2Results posted
- Lenvatinib and Iodine Therapy in Treating Patients With Radioactive Iodine-Sensitive Differentiated Thyroid CancerTerminatedNCT03506048Phase 2Results posted
- Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)CompletedNCT02973997Phase 2Results posted
- Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid CancerCompletedNCT02393690Phase 2Results posted
- Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid CancerActive, not recruitingNCT02152995Phase 2Results posted
- Pre-Operative Nodal Staging of Thyroid Cancer Using USPIO MRI: Preliminary StudyCompletedNCT01927887Not applicableResults posted
- Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid CancerCompletedNCT01811212Phase 2Results posted
- Dabrafenib With or Without Trametinib in Treating Patients With Advanced Differentiated Thyroid CancerCompletedNCT01723202Phase 2Results posted
- Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid CancerCompletedNCT01208051Phase 1/2Results posted
- Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine TherapyCompletedNCT00729157Phase 2Results posted
- Sutent Adjunctive Treatment of Differentiated Thyroid CancerCompletedNCT00668811Phase 2Results posted
- Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid CancerCompletedNCT00519896Phase 2Results posted
- Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by SurgeryCompletedNCT00381641Phase 2Results posted
- REVLIMID® (Lenalidomide) for Therapy of Radioiodine-Unresponsive Papillary and Follicular Thyroid CarcinomasCompletedNCT00287287Phase 2Results posted
- Suberoylanilide Hydroxamic Acid in Treating Patients With Metastatic and/or Locally Advanced or Locally Recurrent Thyroid CancerCompletedNCT00134043Phase 2Results posted
- Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid CancerCompletedNCT00118248Phase 2Results posted
- Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine TherapyCompletedNCT00104871Phase 2Results posted
- Romidepsin in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Has Not Responded to Radioactive IodineCompletedNCT00098813Phase 2Results posted
- Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131CompletedNCT00085293Phase 2Results posted
- Incidental Thyroid Cancer in Cases With Inflammatory Thyroid LesionCompletedNCT07652450Not applicable
- Long-term Survival Outcomes of Total Thyroidectomy and Radioactive Iodine Therapy in Unilateral T3/T4 FTCCompletedNCT06437873
- Hürthle Cell Carcinoma and Follicular Thyroid CarcinomaCompletedNCT05968196
- Radioiodine Planar and a SPECT/CT Imaging With Iodine-123 for Evaluation of Follicular Thyroid Nodules Prior to SurgeryTerminatedNCT05591092
- Evaluation of 18F-TFB PET/CT Scan in Patients With Differentiated Thyroid CancerTerminatedNCT05575440
- Correlation Between Various Urinary Exosomal Protein Biomarkers and Pathological Manifestation in Thyroid Follicular Neoplasm: Early and Pre-operative Diagnosis of Follicular Thyroid CancerActive, not recruitingNCT05463107
- Evaluation of 177Lu-DOTA-EB-FAPI in Patients With Metastatic Radioactive Iodine Refractory Thyroid CancerCompletedNCT05410821Phase 1
- Aberrant Helix Pomatia Agglutinin Binding Glycan Expression in Follicular Thyroid TumoursCompletedNCT05052359
- Urinary Exosomal Biomarkers of Thyroglobulin and Galectin-3 for Prognosis and Follow-up in Patients of Thyroid CancerActive, not recruitingNCT04948437
- PDR001 Combination Therapy for Radioiodine-Refractory Thyroid CancerActive, not recruitingNCT04544111Phase 2
- Psychological Impact of a Sophrological Accompaniment During the Announcement of Thyroid CancerStatus unknownNCT03639662Not applicable
- Anaplastic Thyroid Cancer and Follicular Thyroid Cancer-derived Exosomal Analysis Via Treatment of Lovastatin and Vildagliptin and Pilot Prognostic Study Via Urine Exosomal Biological Markers in Thyroid Cancer PatientsCompletedNCT02862470
- Metabolic Effects of Synthetic Thyroid Hormone for Thyroid Cancer TreatmentCompletedNCT01441154
- Iodine I 131 and Pazopanib Hydrochloride in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer Previously Treated With Iodine I 131 That Cannot Be Removed By SurgeryCompletedNCT01413113Phase 1
- IoN- Is Ablative Radio-iodine Necessary for Low Risk Differentiated Thyroid Cancer PatientsActive, not recruitingNCT01398085Phase 2/3
- A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid TumorsCompletedNCT01100619Phase 1
- Photodynamic Therapy Using HPPH in Treating Patients Undergoing Surgery for Primary or Recurrent Head and Neck CancerCompletedNCT00470496Phase 1
- Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid CancerTerminatedNCT00095693Phase 2
- Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung CancerCompletedNCT00068497Not applicable
- Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/NeuCompletedNCT00004074Phase 1